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cal antipsychotics, including use and average daily dose by chemical, use in community 
and long-term care settings, as well as use among seniors with and without claims 
for anti-dementia drugs. RESULTS: The rate of antipsychotic use among seniors in 
all provinces grew from 4.3% in 2001–2002 to 5.0% in 2006–2007. The rate of 
growth of antipsychotic use slowed during the study period from an average of 5.2% 
per year between 2001–2002 to 1.0% between 2003–2004 and 2006–2007. Antipsy-
chotic use was highest among females and seniors 85 and older. There was a continued 
shift to the use of atypical agents from typical agents over the study period. In 
2006–2007, 37.7% of senior nursing home residents in three provinces had claims for 
atypical antipsychotics, compared to only 2.6% of seniors living in the community. 
When looking at only seniors with claims for anti-dementia drugs, use of atypical 
antipsychotics was higher among nursing home residents. CONCLUSIONS: 
This analysis provides insight into antipsychotic use among seniors. Antipsychotic 
use increased throughout the study period, although its rate of growth declined fol-
lowing the release of the new safety information. The rate of atypical antipsychotic 
use was higher in seniors living in nursing homes and in those taking anti-dementia 
drugs.
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OBJECTIVES: Examine arrest outcomes for adults with severe mental illness (SMI) 
treated with second generation atypical antipsychotics (SGAs), ﬁrst generation anti-
psychotics (FGAs) or no medication. METHODS: Continuous medication episodes 
lasting at least 60 days between 2004 and 2008 were examined (N individuals = 
36,519; N episodes = 222,928). Medication episodes were coded as: 1) SGA—clozap-
ine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or RLAI; 2) FGA—
any other antipsychotic medication; or 3) none. Outpatient services included at least 
one behavioral health visit every 30 days of an episode. Data are from Florida’s 
Medicaid program and Department of Law Enforcement. Arrest was modeled as a 
function of medication controlling for time, outpatient treatment, and relevant demo-
graphic and diagnostic characteristics using survival analysis. Models also adjusted 
for the baseline propensity to receive an SGA. RESULTS: Five percent of medication 
episodes contained an arrest. There was a trend (p = 0.10) for the main effect of SGA 
episodes to reduce arrests compared to FGA episodes; however, the interaction 
between outpatient services and SGA episodes was signiﬁcant (Hazard Ratio [HR]: 
0.80; 95% Conﬁdence Limits [CL]: 0.65–0.99; p < 0.05) such that at least one out-
patient visit every 30 days of an SGA episode reduced arrests compared to FGA 
episodes. Compared to no medication episodes, the interaction between outpatient 
treatment by SGA episodes reduced arrests (HR: 0.87; 95% CL: 0.76–0.99; p < 0.05) 
whereas outpatient treatment by FGA episodes did not reduce arrests. Substance 
abuse, medication gaps, and prior arrest increased risk of subsequent arrest. CON-
CLUSIONS: There was a statistically signiﬁcant interaction between outpatient visits 
and treatment that indicated an association between a reduced risk of arrest for SGAs 
compared to FGAs and no medication periods. These ﬁndings suggest the importance 
of both effective antipsychotic medications and outpatient interventions to reduce 
arrests in adults with SMI.
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OBJECTIVES: To examine the patterns and associated factors of health care expen-
ditures in the pediatric population with depression using 2005–2006 Medical Expen-
diture Panel Survey (MEPS) data. METHODS: Analysis was based on a nationally 
representative sample of children and adolescents aged 5 to 17 years with an ICD-
9-CM diagnosis of depression from the 2005–2006 MEPS. Multivariate model within 
the conceptual framework of Andersen’s Behavioral Model was used to examine 
factors related to health care expenditures in children and adolescents with depression. 
Smearing techniques were used to transform estimated log costs into actual costs. 
RESULTS: Analysis of annual expenditures in children and adolescents with depres-
sion revealed that average total and out-of pocket payments per child with depression 
were $3963 (95% CI 2453–5471) and $672 (95% CI 377–973), respectively. Pre-
scription-related expenditures in children and adolescents with depression revealed 
that average total and out-of pocket payments were $1096 (31% of total) and $343 
(51% of total), respectively. Multivariate model revealed that predisposing, enabling, 
and need factors were associated with total health expenditures. Among the predispos-
ing characteristics, age (+$3069) and family history of psychiatric disorders (+$2066) 
were positively associated with total expenditures. Among the enabling characteristics, 
children and adolescents having usual source of care provider had lower total expen-
ditures (−$3523) than those without usual source of care. Hyperactivity disorders 
(+$4001) and functional impairment (+$1304) increased total expenditures in children 
with depression. CONCLUSIONS: Analysis of MEPS data revealed prescription medi-
cations account for signiﬁcant portion of total and out-of-pocket expenditures. Pre-
disposing, enabling, and need factors play an important role in the overall burden of 
pediatric depression in the United States.
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COST OF PHARMACEUTICAL CARE IN PATIENTS WITH METABOLIC 
SYNDROMES CAUSED BY ATYPICAL ANTIPSYCHOTICS
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OBJECTIVES: The aim of this study was to evaluate the probability of metabolic 
syndrome caused by atypical antipsychotics after long term therapy and the cost of 
pharmacist interventions to improve these metabolic adverse effects. METHODS: A 
total of 431 adults prescribed atypical antipsychotics therapy from 2002 to 2007 were 
retrieved from the claim database. The primary outcome measurement was the prob-
ability of metabolic syndrome caused by atypical antipsychotics after long term 
therapy. The secondary outcome was to evaluate the cost of pharmacist intervention. 
Pharmacist consultation clinic for measuring their waist, buttocks, pharmaceutical 
education and body weight management. Computerized physician order entry alerting 
system for abnormal metabolic chemical variables remind physician to attend patients 
abnormal laboratory data and adjust the treatment regimen. RESULTS: The primary 
outcomes showed that the total rate of metabolic syndrome induced by atypical 
antipsychotics were 16% (48/298). The secondary outcome, the abnormal BMI value 
of 50 patients,who received pharmacist consultation services, decreased from 52% to 
41%. After establishment of computerized physician order entry alerting system, the 
possibility of patients’ abnormal biochemical values induced by atypical antipsychotics 
decreased from 4.28% (33/771) to 1.23% (8/651). The clinical effectiveness of this 
research included the occurrence of dyslipidaemia and disorders of glucose homeosta-
sis associated with cardiovascular disease. The total direct medical cost saved for this 
pharmaceutical care was approximately NT 1,428,250 during this study period. 
CONCLUSIONS: All patients receiving atypical antipsychotic agents associated with 
metabolic adverse events should be routinely monitored on weight gain, abnormal 
blood glucose and lipid levels. The effective communication and collaboration with 
mental health care and pharmaceutical care services is an effective model for caring 
patients with mental disease.
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OBJECTIVES: The aim of the study is to determine the impact of black box warning 
and other regulatory changes related to antidepressants on the prescription pattern of 
antidepressants for children and adolescents by ofﬁce based physicians. METHODS: 
Data for the present study was obtained from National Ambulatory Medical Care 
Survey (NAMCS), 2003–2005. Patients under the age of 18 were included in the study, 
if they had at least one antidepressant prescribed. Prescription pattern of antidepres-
sant was assessed in terms of rate of antidepressants prescribed, type of antidepres-
sants, physician specialty and demographics such as age, gender and race. Descriptive 
statistics were carried out using SPSS 17. RESULTS: The number of visits with at least 
one antidepressant prescribed for children and, adolescents were 228 (10.37%), 213 
(9.23%) and, 184 (6.81%) for year 2003, 2004 and 2005 respectively. Rate of pre-
scribing Fluoxetine per 100 antidepressants increased from 17.16 in 2003 to 19.13 in 
2004 and 26.26 in 2005, rate of prescribing Paroxetine decreased from 17.91 in 2003 
to 11.30 in 2004 to 11.11 in 2005. The number of antidepressants prescribed by 
psychiatrists decreased from (186, 81.6%) in 2003 to (164, 77%) in 2004 and (135, 
73.6%) in 2005. CONCLUSIONS: The rate of prescribing antidepressants to children 
and adolescents decreased after FDA black box warning in 2004. The prescription 
rate of Fluoxetine increased after FDA approved it for children and adolescents in 
2004 while prescription rate of Paroxetine decreased after 2003 when FDA recom-
mended that it shouldn’t be used in pediatric patients. No changes were observed in 
antidepressant prescribing by primary care physicians.
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OBJECTIVES: To identify the extent to which psychotropic medication prescribing 
for bipolar spectrum disorders differs for younger children as compared with older 
children. Identifying if younger children receive similar diagnoses and treatments as 
older children is important, as this may inform clinical trial designs and the degree to 
which medication use in older children can be generalized to younger children. 
METHODS: A retrospective cohort was constructed using 2005–2007 MarketScan 
data. Patients under 18 years of age, with one inpatient or two outpatient insurance 
claims for any bipolar spectrum disorder were included. Patients whose pharmacy 
data were unavailable or who were not continuously insured from diagnosis to 30 
days after diagnosis were excluded. Ages 9 and under were considered “younger” 
and ages 10–17 were considered “older.” Medication use was summarized as therapies 
prescribed within 30 days after the last bipolar diagnosis. Psychotropic medication 
use included lithium, anticonvulsants, antipsychotics, antidepressants, or stimulants. 
RESULTS: Approximately 11,000 children were eligible for inclusion in each 
study year. In 2007, 64.1% of younger and 62.8% of older children received psycho-
tropic medications for bipolar disorder. Younger children were less likely than older 
children to receive lithium (8.2% versus 11.6%), anticonvulsants (36.2% versus 
